News Bafiertam, a Bioequivalent of Tecfidera, Receives Tentative OK from FDA for RRMS Bafiertam, a Bioequivalent of Tecfidera, Receives Tentative OK from FDA for RRMS by Alberto Molano, PhD | January 4, 2019 Share this article: Share article via email Copy article link Banner Life SciencesĀ has received tentative approval from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) for Bafiertam (monomethyl fumarate), a novel bioequivalent of Biogenās Tecfidera (dimethyl fumarate) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Final approval is expected no later than June 2020, the company announced. According to the FDA, Bafiertam satisfies the bioequivalence, safety, efficacy, and quality standards required for approval. Bioequivalence means that equivalent doses of two medicines provide the same amount of active ingredient, at the same rate, and at the correct site of action. The active ingredient of Bafiertam is monomethyl fumarate, Ā a compound that can cross the blood-brain barrier. Tecfidera is quickly converted fromĀ dimethyl fumarate into monomethyl fumarate in the body. Tecfidera is thus considered to be a “prodrug” of Bafiertam, meaning it isĀ a pharmacologically inactive compound that can be converted to a pharmacologically active one once inside the body. Tecfidera has been shown to reduce the relapse rate in MS patients compared to placebo.Ā Although the mechanism of action of Tecfidera and Bafiertam is still not well understood, both have been shown to activate a transcription factor known as nuclear factor (erythroid-derived 2)-like 2 (Nrf2), which may protect neuronal cells against oxidative stress.Ā In MS, inflammation and oxidative stress damage the protectiveĀ myelin sheathĀ of nerve fibers (axons). Discuss the latest research in the MS News Today forums! In addition, Tecfidera has been shown to alter the profile of the immune system, reducing the number of blood lymphocytes (particularly the pro-inflammatory subsets), and to block pro-inflammatory cytokine production, shifting the overall immune response to an anti-inflammatory profile. Biogen claimed that Bafiertam would infringe patents related to Tecfidera, opening a litigation process. However, a lawsuit was dismissed in September 2018, so full FDA approval is expected once Biogenās current patent expires on June 20, 2020. Approval may come sooner depending on the outcome of pending litigation with Biogen regarding this patent. āWe are very pleased with the FDAās tentative approval and this important milestone brings us one step closer to providing another treatment option to patients living with relapsing-remitting multiple sclerosis,ā Franck Rousseau, MD, chief executive officer of Banner Life Sciences, said in a press release. āIn anticipation of final approval, we will establish our commercial vehicle, continue developing the clinical profile of Bafiertam and refine our strategic positioning for this important drug,ā Rousseau said. Print This Page About the Author Alberto Molano, PhD Alberto Molano was born in BogotĆ”, Colombia. He studied medicine at Universidad del Rosario and obtained a Ph.D. in Immunology from Weill Cornell Graduate School of Medical Sciences in New York. He conducted research and authored or co-authored twenty publications on molecular and cellular immunology, autoimmunity, immunology of aging and parasite immunology. Tags Bafiertam, Banner Life Sciences, bioequivalence, Biogen, FDA, monomethyl fumarate, RRMS, Tecfidera
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS
April 18, 2024 Columns by Benjamin Hofmeister Learning how to write a ‘SOAP’ note feels different after an MS diagnosis
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8